Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro

Antiviral Research

Volumn 86, Issue 3, 2010, Pages 241-245

  Bader, Ted ^a   Korba, Brent ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Entecavir; Hepatitis B virus; Mevalonate; Simvastatin; Tenofovir

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; MEVALONIC ACID; NUCLEOSIDE ANALOG; SIMVASTATIN; TENOFOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; DRUG SYNERGISM; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; SIMVASTATIN;

HEPATITIS B VIRUS; LETTUCE MOSAIC VIRUS;

EID: 77952669197     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.02.325     Document Type: Article

References (28)

1. Abraldes J.G., Albillos A., Bañares R., Turnes J., González R., García-Pagán J.C., Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009, 136:1651-1658.
2. Bader T., Fazili J., Madhoun M., Aston C., Hughes D., Rizvi S., Seres K., Hasan M. Fluvastatin inhibits hepatitis C replication in humans. Am. J. Gastroenterol. 2008, 103:1383-1389.
3. Bader T., Korba B. Drug-resistant and wild-type strains of HBV are inhibited equally by simvastatin. Hepatology 2008, 48(Suppl. 1):A877.
4. Cohen D.E., Anania F.A., Chalasani N. An assessment of statin safety by hepatologists. Am. J. Cardiol. 2006, 97(Suppl. 8A):77C-81C.
5. Delang L., Paeshuyse J., Vliegen I., Leyssen P., Obeid S., Durantel D., Zoulim F., Op de Beeck A., Neyts J. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009, 50:6-16.
6. Diminsky D., Schirmbeck R., Reimann J., Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997, 15:637-647.
7. El-Serag H.B., Johnson M.L., Hachem C., Morgana R.O. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009, 136:1601-1608.
8. Germershausen J.I., Hunt V.M., Bostedor R.G., Bailey P.J., Karkas J.D., Alberts A.W. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. 1989, 158:667-675.
9. Ha C.E., Ha J.S., Theriault A.G., Bhagavan N.V. Effects of statins on the secretion of human serum albumin in cultured HepG2 cells. J. Biomed. Sci. 2009, 16:32.
10. Hayashi K., Kurokawa J., Nomura S., Kuga Y., Ohkura Y., Kajiyama G. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochim. Biophys. Acta 1993, 1167:223-225.
11. Ikeda M., Abe K., Yamada M., Dansako H., Naka K., Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006, 44:117-125.
12. Jacobson I.M. Combination therapy for chronic hepatitis B: ready for prime time?. J. Hepatol. 2008, 48:687-691.
13. Johnson, P., Epidemiology of hepatocellular cancer presented at the European study for the study of liver monothematic conference on liver cancer. Prague. 2008 (accessed on December 30, 2008 at ). http://www.multiwebcast.com/easl/2008/prague.
14. Khurana V., Saluja A., Caldito G., Fort C., Schiff E. Statins are protective against hepatocellular cancer in patients with hepatitis C infection: half a million US veterans' study. Gastroenterology 2005, 128(Suppl 2):A714.
15. Korba B.E. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res. 1996, 29:49-51.
16. Korba B.E., Milman G. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res. 1991, 15:217-228.
17. Korba B.E., Gerin J.L. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 1992, 19:55-70.
18. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Rasenack J., Bzowej N., Naoumov N.V., Di Bisceglie A.M., Zeuzem S., Moon Y.M., Goodman Z., Chao G., Constance B.F., Brown N.A. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007, 357:2576-2588.
19. Lin Y.L., Shiao M.S., Mettling C., Chou C.K. Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion. Virology 2003, 314:253-260.
20. Lok A., McMahon B. Chronic hepatitis B. Hepatology 2007, 45:503-539.
21. Mauro V.F. Clinical pharmacokinetics and practical applications of simvastatin. Clin. Pharmacokinet. 1993, 24:195-202.
22. Pawlotsky J.M., Dusheiko G., Hatzakis A., Lau D., Lau G., Liang T.J., Locarini S., Martin P., Richman D.D., Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405-415.
23. Pentikainen P.J., Saraheimo M., Schwartz J.I., Amin R.D., Schwartz M.S., Brunner-Ferber F., Rogers J.D. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J. Clin. Pharmacol. 1992, 32:136-140.
24. Potena L., Frascaroli G., Grigioni F., Lazzarotto T., Magnani G., Tomasi L., Coccolo F., Gabrielli L., Magelli C., Landini M.P., Branzi A. Hydroxymethyl-glutaryl coenzyme A reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 2004, 109:532-536.
25. Reddy K.R., Matelich M.C., Ugarkar B.G., Gómez-Galeno J.E., DaRe J., Ollis K., Sun Z., Craigo W., Colby T.J., Fujitaki J.M., Boyer S.H., van Poelje P.D., Erion M.D. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J. Med. Chem. 2008, 51:666-676.
26. Schönbeck U., Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 2004, 109:18-26.
27. Ye J., Wang C., Sumpter R., Brown M.S., Goldstein J.L., Gale M. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15865-15870.
28. Zafra C., Abraldes J.G., Turnes J., Berzigotti A., Fernández M., Garcia-Pagán J.C., Rodés J., Bosch J. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004, 126:749-755.